• BowelScreen Australia Pharmacy
  • Prevent Bowel Cancer
  • Making Real Change Happen
  • 1
  • 2
  • 3
BowelScreen Australia® is a Bowel Cancer Australia initiative
launched in 2010 to provide greater access to bowel cancer screening.

Medical guidelines recommend screening every 1-2 years from age 50 for Australians at average risk.1

 Talk to your GP or pharmacist today about BowelScreen Australia®
or purchase a test online or by phoning 1800 555 494.
GP practices or community pharmacies interested in stocking BowelScreen Australia® tests,
please call 1800 55 65 75 and select Option 3 when prompted. 

BowelScreen Australia® uses a clinically proven, sensitive and reliable faecal immunochemical test (FIT).

The Australian designed and manufactured test and accredited pathology services are provided by Clinical Genomics.  

Screening using a faecal immunochemical test (FIT) is one of the most effective ways to reduce the risk of bowel cancer.

BowelScreen Australia® tests come complete with full instructions, a dedicated customer helpline, as well as a reminder service.
No faecal handling, diet or medication changes are required to perform the test, which can be completed in the privacy of your own home.
The recommended retail price of the BowelScreen Australia® test is $39.95 (inc. GST).
The price includes the test kit, pathology analysis, result reporting to the participant and their nominated GP2 and return postage. 

The Australian Government is gradually phasing in the National Bowel Cancer Screening Program by 2020.

Eligible Australians will receive a free bowel cancer screening test in the mail and are encouraged to complete and return it.

For information regarding start dates of each phase and eligible ages please
visit the National Bowel Cancer Screening (NBCSP) webpage or contact 1800 118 868.

 1. GESA, Early Detection, Screening and Surveillance for Bowel Cancer, 2011; 
NHMRC, Clinical Practice Guidelines for Surveillance Colonoscopy – in adenoma follow-up; following curative resection of colorectal cancer; and for cancer surveillance in inflammatory bowel disease, 2011. 
2. Please note, all results must be sent to a nominated GP.  The test cannot be processed without contact details of your GP.